What is ADUS's 12-month stock price target?

Addus HomeCare Corporation (ADUS) carries a 12-month consensus base price target of $134.8 (+7.2% from $125.75), with a bull-case target of $159.06 and a bear-case floor of $103.11.

Stock Ratings / Health Care / ADUS / forecast

WGS (47) PRVA (53) AVAH (65) TDOC (55) ⌘ Pro Terminal →

Addus HomeCare Corporation (ADUS) 12-Month Stock Forecast & Price Target Cone

Q: Is ADUS stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ADUS B (Buy — BUY) with an RQD Confidence score of 74/100.

$125.75 +0.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $126.09

Addus HomeCare Corporation (ADUS) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (32.5% gross margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $2.34B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADUS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Addus HomeCare Corporation (NASDAQ: ADUS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $125.75 (+0.17% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, ADUS ranks #40 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADUS compare to WGS and PRVA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), ADUS carries a Roarable B (74/100 RQD), trailing P/E of 24.2x, gross margin of 32.5%, and ROIC of 9.1%. By comparison, WGS (GeneDx Holdings Corp. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC -4.1%, cap $2.06B) and PRVA (Privia Health Group Inc.) posts a D+ grade (53/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.74B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADUS?

▼

Per ADUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468328), Addus HomeCare Corporation generated $1.42B in revenue (+23.2% YoY), $95.9M in net income, and $103.8M in free cash flow against $1.44B in total assets and $121.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $126.09 (+0.27%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 7.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADUS)Realized 20D OHLCV Swing Band: ±4.7%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY ADUS SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (23% of score)

20D Institutional Volume Accumulation (±4.7% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (20% of score)

Altman Z-Score 5.83 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Cash Engine Quality12/20 pts (-8 pt drag)

Capital intensity & 9.7% operating margin leave 8 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$114.53+3.1% Next Q

Q2 (-2Q)

Grade B-$118.03+2.7% Next Q

Q3 (-1Q)

Grade B$121.24+3.7% Next Q

Current

Grade B$125.75+7.3% Hist 90D α

Trajectory: B- (66) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ADUS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, ADUS faces multiple-compression risk if 24.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 30.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($117.17) or 200D SMA ($106.52) invalidates the momentum regime and cuts Target Base ($134.80) toward Bear Floor ($103.11).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ADUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ADUS Position Size: $10,000

Shares at $125.75: 79.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $103.11

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $134.80

$10,720

+$720 (+7.2%)

12M Bull Case BreakoutTarget $159.06

$12,649

+$2,649 (+26.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 23● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$140	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$150	69%	B
JP MorganUS Large-Cap Research	HOLD	$119	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ADUS Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.60%⚡ TESTING RESISTANCE

2026-11-03O $124.3H $125.8L $124.3C $125.8VOL 300.4K

RES: $126.8SUP: $111.2SMA50: $117.2SMA200: $106.5

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADUS Butterfly Map → + Track ADUS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

17.9%/yr Implied 5Y Growth

vs. +23.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ADUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADUS)

Health Care Rank #40 of 1015 ⚔️ WGS vs ADUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADUS vs. WGS, PRVA, AVAH, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Addus HomeCare Corporation (ADUS) ranks #40 by composite RQD confidence (74/100, grade B) and #226 by equity capitalization ($2.34B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADUS ACTIVE Addus HomeCare Corporation	B	74/100	24.2x	32.5%	9.1%	+0.17%	$2.34B	Benchmark Subject
WGS GeneDx Holdings Corp. (Class A)	D	47/100	—	69.7%	-4.1%	-7.20%	$2.06B	/wgs-vs-adus →
PRVA Privia Health Group Inc.	D+	53/100	122.6x	—	10.5%	-0.93%	$2.74B	/prva-vs-adus →
AVAH Aveanna Healthcare Holdings Inc.	C	65/100	—	33.3%	15.7%	-0.30%	$2.87B	/avah-vs-adus →
TDOC Teladoc Health Inc.	D+	55/100	—	—	-17.0%	+1.41%	$1.55B	/tdoc-vs-adus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001468328 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Addus HomeCare Corporation (ADUS) reported GAAP revenue of $1.42B (+23.2% vs. FY2024 revenue of $1.15B , and +34.4% cumulative change since FY2023) , GAAP net income of $95.9M, operating cash flow of $111.5M, and free cash flow of $103.8M (-6.0% YoY). On the balance sheet, ADUS closed FY2025 with $1.44B in total assets against $121.0M in total debt (Altman Z-Score: 5.83, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.42B	$95.9M	$111.5M	$103.8M	$1.44B	$121.0M
FY2024 (FY)	2024-12-31	$1.15B	$73.6M	$116.4M	$110.4M	$1.41B	$218.4M
FY2023 (FY)	2023-12-31	$1.06B	$62.5M	$112.2M	$112.2M	—	—

3. ADUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ADUS compare to WGS and PRVA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ADUS?

Where is ADUS trading relative to its 50-day, 200-day, and 52-week technical levels?

ADUS last traded at $125.75 (+0.17% on volume of 508,511 shares), positioning the stock +7.32% above its 50-day simple moving average ($117.17) and +18.05% above its 200-day simple moving average ($106.52). Across its 52-week range of $87.95 to $126.62, ADUS sits at the 97.8% percentile with a 14-day RSI of 70.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.7% ($119.84 to $131.66).

Direct Sub-Reports: ADUS RQD Cockpit ADUS 12M Forecast ADUS Earnings & Move ADUS Dividends & DRIP ADUS Insiders & 13F ADUS Whale Options ADUS Profit Sankey ADUS News & Why

ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ SEC XBRL & RQD VERIFIED

ADUS — Addus HomeCare Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Addus HomeCare Corporation (ADUS) earns a live Roarable RQD composite score of 74/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $125.75 (+0.17% 1D, market capitalization $2.34B).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.1%, gross margin of 32.5%, operating margin of 9.7%, and free cash flow yield of 4.47%.
Whale 13F & Options Flow (17/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (15/20) + Forensic Balance Sheet (15/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.83, Piotroski F-Score of 9/9, and Debt/Equity of 0.11x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Addus HomeCare Corporation is a NASDAQ-listed issuer classified in the Health Care sector and Medical/Nursing Services industry. Its market capitalization is $2.3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Addus HomeCare Corporation (ADUS) reported $1.42B in annual revenue (up from $1.15B in FY2024, +23.2% YoY) and $95.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.06B revenue, $62.5M net income) through FY2025, ADUS scaled operating cash flow to $111.5M and free cash flow to $103.8M, backed by $1.44B in total assets against $121.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B • RQD 74/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $87.95 – $126.62 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 24.2x trailing P/E and 16.8x EV/EBITDA against 9.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the stated beta of 1.0: — 2nd-order bottlenecks: — An investor should treat the absence of mapped links as a gap in the analysis rather than as evidence of independence.

Key Question #1: Can ADUS sustain or expand its 9.7% operating margin and 9.1% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.42B and free cash flow of $103.8M, how will capital allocation balance growth reinvestment against $121.0M in total debt?
Key Question #3: How sensitive is ADUS's 20.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ADUS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Addus HomeCare Corporation (ADUS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADUS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Addus HomeCare Corporation (ADUS) Stock Forecasts

Yahoo Finance report covering Addus HomeCare Corporation (ADUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Addus HomeCare Corporation Estimates – NASDAQ:ADUS

TradingView report covering Addus HomeCare Corporation (ADUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Addus HomeCare (ADUS) Q3 earnings report preview: what to look for

Yahoo Finance report covering Addus HomeCare Corporation (ADUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Addus HomeCare And Two Other Stocks Trading Below Estimated Intrinsic Value

Simply Wall St report covering Addus HomeCare Corporation (ADUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Addus HomeCare Announces Third Quarter 2026 Earnings Release and Conference Call

Yahoo Finance report covering Addus HomeCare Corporation (ADUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(ADUS) as a Liquidity Pulse for Institutional Tactics

Stock Traders Daily report covering Addus HomeCare Corporation (ADUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 1d ago

Can Hims & Hers Stock Rally 50% After This Dip?

For questions about this article or underlying research, email help@trefis.com.

Read Full Source ↗

🔴 RISK WATCH Yahoo • 6d ago

Can Hims & Hers Stock Fall 30%?

For questions about this article or underlying research, email help@trefis.com.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADUS Bull vs. Bear Conversation Board — What's Your Call at $125.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADUS 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $149.39 (+19.0%)

📌 Pinned Debate

Per the RQD rating, forensic balance sheet strength (Altman Z 5.83, Piotroski F 9/9, Debt/Equity 0.11) combined with institutional accu

Don't sleep on ADUS's setup in Health Care. Per the RQD rating, forensic balance sheet strength (Altman Z 5.83, Piotroski F 9/9, Debt/Equity 0.11) combined with institutional accumulation supports the Roarable Buy verdict.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (74/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@SiliconVal_Bull Agree on the RQD 74/100 quality, though with 1.0 beta I'm scaling in with half-size at $125.54 and keeping dry powder in case we test $116.75.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $105.45 (-16.0%)

Spot @ $125.54

Per the RQD rating, the Fundamental Cash Engine scores only 12 / 20 with ROIC of 9.1% and FCF yield of 4.47%, and FCF declined from $11

I respect the product at Addus HomeCare Corporation, but the stock at $125.54 is a different story. Per the RQD rating, the Fundamental Cash Engine scores only 12 / 20 with ROIC of 9.1% and FCF yield of 4.47%, and FCF declined from $112.2M to $103.8M.. FCF yield is 4.47% and RQD sits at 74/100 (B) — why pay up here when you can wait for next quarter's numbers?